The invention relates to oligomeric peptides with biological activity against HIV infection having the amino acid sequence (Z<；SUB>；1<；/SUB>；-LE-X<；SUB>；1<；/SUB>；-IP-X<；SUB>；2<；/SUB>；-X<；SUB>；3<；/SUB>；-X<；SUB>；4<；/SUB>；-P-X<；SUB>；5<；/SUB>；-X<；SUB>；6<；/SUB>；-X<；SUB>；7<；/SUB>；-X<；SUB>；8<；/SUB>；-X<；SUB>；9<；/SUB>；-X<；SUB>；10<；/SUB>；-K-X<；SUB>；11<；/SUB>；-X<；SUB>；12<；/SUB>；-X<；SUB>；13<；/SUB>；-X<；SUB>；14<；/SUB>；-X<；SUB>；15<；/SUB>；-Z<；SUB>；2<；/SUB>；)<；SUB>；n<；/SUB>；, wherein n indicates the number of monomeric peptide chains, whereby n is 2, 3 or 4； X<；SUB>；1 <；/SUB>；is a lysine, alanine, or aspartic acid； X<；SUB>；2 <；/SUB>；is a cysteine, methionine or isoleucine； X<；SUB>；3 <；/SUB>；is a serine, cysteine, lysine or glycine； X<；SUB>；4 <；/SUB>；is an isoleucine, alanine, phenylalanine or cysteine； X<；SUB>；5 <；/SUB>；is a proline, D-proline or a substituted L- or D-proline； X<；SUB>；6 <；/SUB>；is a cysteine or glutamic acid； X<；SUB>；7 <；/SUB>；is an amino acid with a hydrophobic or an aromatic side chain or cysteine； X<；SUB>；8 <；/SUB>；is an amino acid with a hydrophobic or an aromatic side chain or cysteine； X<；SUB>；9 <；/SUB>；is an amino acid with an aromatic side chain； X<；SUB>；10 <；/SUB>；is a glycine, alanine or asparagine； X<；SUB>；11 <；/SUB>；is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid； X<；SUB>；12 <；/SUB>；is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid； X<；SUB>；13 <；/SUB>；is an amino acid with a hydrophobic or an aromatic side chain； X<；SUB>；14 <；/SUB>；is an amino acid with a hydrophobic or an aromatic side chain； X<；SUB>；15 <；/SUB>；is a phenylalanine or deletion； Z<；SUB>；1 <；/SUB>；is
